QINGDAO, China, June 30, 2025 /PRNewswire/ -- Hisense, a leading brand in global consumer electronics and home appliances, is showcasing its AI leadership at the FIFA Club World Cup 2025â„¢ with the bold pitch-side message "AI YOUR LIFE," reflecting the brand's vision of human-centric innovation through intelligent technology.
As one of the earliest consumer tech brands to explore AI, Hisense is integrating intelligent features across its product portfolio. Today, at the core of Hisense's intelligent ecosystem is the Hi-View AI Engine X—its most powerful AI processor yet. Powered by deep neural networks, it learns and adapts like a human brain, optimizing picture and sound across all content, from fast-paced sports to cinematic films and immersive gaming.
Driving the next generation of ULED AI TVs, Hi-View AI Engine X powers four key pillars: AI Picture for lifelike contrast, color, and motion; AI Sound for adaptive clarity and immersive acoustics; AI Scenario for automatic mode switching; and AI Energy for top performance with greater efficiency. Together, they create a more immersive, intelligent way to enjoy every match, goal, and moment on screen.
Beyond the screen, Hisense expands smart connectivity in the home through ConnectLife. From AI-guided cooking to personalized laundry care, users enjoy seamless, scenario-based intelligence. The PureFlat Smart Series refrigerator, with its 21-inch screen, serves as a convenient hub to manage appliances with ease.
For Hisense, whether it's screen or appliance, the essence is home — and the essence of home is love. Now enhanced by AI, that belief evolves—technology becomes more intuitive, responsive, and emotional. As global audiences celebrate football's finest moments, Hisense invites everyone to "Own the Moment" with intelligent products that understand, adapt, and inspire.
About Hisense
Hisense, founded in 1969, is a globally recognized leader in home appliances and consumer electronics with operations in over 160 countries, specializing in delivering high-quality multimedia products, home appliances, and intelligent IT solutions. According to Omdia, Hisense ranks No. 2 worldwide in total TV volume shipments (2022-2024) and No. 1 globally in the 100-inch and over TV segment (2023- Q12025). As the first official partner of the FIFA Club World Cup 2025â„¢, Hisense is committed to global sports partnerships as a way to connect with audiences worldwide.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Hisense Showcases AI Technology Strength with "AI YOUR LIFE" Message at FIFA Club World Cup 2025™
Hisense Showcases AI Technology Strength with "AI YOUR LIFE" Message at FIFA Club World Cup 2025™
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
